Internal Medicine, Gastroenterology · Los Angeles, CA
NPI
1356482392
Since 2007
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
4
Medicare group memberships
Hospitals
4
Hospital affiliations
1701 E Cesar E Chavez Ave Ste 510
Los Angeles, CA, 90033
Phone (323) 987-1301
Groups this clinician bills Medicare through
Medicare paid, 2024
$71K
733 services
Medicare patients, 2024
342
Average age 71
Drug cost, 2024
$364K
1,077 prescriptions
Company payments, 2025
$1,549
From 10 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Alireza Tabesh was code 99213 (office e&m - established), 175 times for 113 patients. In total Alireza Tabesh billed 733 services in 29 codes, and Medicare paid $71K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2009-12-15.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 175 | 113 | $72.72 | $13K |
| 99222 Hospital E&M - Initial | Facility | 146 | 143 | $108.62 | $16K |
| 43239 Upper GI Endoscopy | Facility | 84 | 83 | $85.36 | $7,170 |
| 99232 Hospital E&M - Subsequent | Facility | 78 | 53 | $64.31 | $5,016 |
| 99203 Office E&M - New | Office | 54 | 54 | $71.80 | $3,877 |
| 45380 Lower GI Endoscopy - Other | Facility | 49 | 49 | $102.67 | $5,031 |
| 45385 Colonoscopy - Lesion Removal | Facility | 30 | 30 | $217.60 | $6,528 |
| 99204 Office E&M - New | Office | 24 | 24 | $124.48 | $2,988 |
| 45378 Lower GI Endoscopy - Other | Facility | 19 | 19 | $136.37 | $2,591 |
| 99214 Office E&M - Established | Office | 16 | 16 | $104.37 | $1,670 |
| 43246 Upper GI Endoscopy | Facility | 14 | 13 | $156.02 | $2,184 |
By year: 2022 $72K for 701 services; 2023 $74K for 727 services; 2024 $71K for 733 services.
Medicare prescription drug claims, 2024
In 2024, the drug Alireza Tabesh prescribed most often to Medicare patients was Sutab (Sod Sulf/Pot Chloride/Mag Sulf), with 191 prescriptions and refills. In total Alireza Tabesh wrote 1,077 Medicare prescriptions that cost $364K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Sutab Sod Sulf/Pot Chloride/Mag Sulf | 191 | 191 | 184 | $30K |
| Linzess Linaclotide | 180 | 303 | 68 | $159K |
| Omeprazole Generic | 154 | 370 | 80 | $2,128 |
| Famotidine Generic | 129 | 245 | 53 | $1,714 |
| Trulance Plecanatide | 67 | 81 | 15 | $43K |
| Pantoprazole Sodium Generic | 53 | 146 | 23 | $548 |
| Dicyclomine Hcl Generic | 47 | 60 | 19 | $668 |
| Ibsrela Tenapanor Hcl | 36 | 38 | 11 | $66K |
| Dexlansoprazole Dr Dexlansoprazole | 21 | 29 | Under 11 | $3,447 |
| Metoclopramide Hcl Generic | 16 | 32 | Under 11 | $84.89 |
| Clonidine Hcl Generic | 14 | 16 | Under 11 | $36.36 |
| Cholestyramine Light Cholestyramine | 13 | 15 | Under 11 | $802 |
| Lubiprostone Generic | 12 | 15 | Under 11 | $799 |
| Sucralfate Generic | 12 | 16 | Under 11 | $3,547 |
| Cholestyramine Cholestyramine (With Sugar) | 11 | 18 | Under 11 | $542 |
Brand drugs: 521 claims; generic drugs: 556 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Alireza Tabesh $1,549 ($1,549 in general payments such as food, travel and fees) from 10 companies. The largest payer was Janssen Biotech, Inc. with $611.
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. JNJ | 16 | $611 |
| Ardelyx, Inc. ARDX | 14 | $486 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $125 |
| Novo Nordisk Inc NVO | 3 | $76.03 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 4 | $75.74 |
| Abbvie Inc. ABBV | 3 | $62.6 |
| Enterra Medical, Inc. | 1 | $43.63 |
| Bioventus LLC BVS | 2 | $33.01 |
| Echosens North America, Inc. | 1 | $22.27 |
| Exact Sciences Corporation EXAS | 1 | $14.07 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.